The 2nd General Assembly was held as a virtual meeting on 8th – 9th March 2021, with around 130 participants from all partners as well as external members of the Scientific Advisory Board and the Patient Specialist Advisory Board. Progress on all work packages was presented and discussed, with particular focus on the current Feasibility Study, lessons learned and preparations for the following Clinical Validation Study. In particular, the impact of the COVID-19 pandemic on the patient recruitment and project timescales was discussed, together with mitigation actions.
